A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

July 31, 2023

Primary Completion Date

May 22, 2026

Study Completion Date

June 12, 2026

Conditions
Hemophilia A, Severe
Interventions
DRUG

Efanesoctocog alfa

Recombinant coagulation factor VIII Fc-von Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN)

Trial Locations (30)

Unknown

Investigational Site, Vienna

Investigational Site, Zagreb

Investigational Site, Brno

Investigational Site, Prague

Investigational Site, Bordeaux

Investigational Site, Le Kremlin-Bicêtre

Investigational Site, Marseille

Investigational Site, Strasbourg

Investigational Site, Berlin

Investigational Site, Frankfurt

Investigational Site, Giessen

Investigational Site, Hamburg

Investigational Site, Athens

Investigational Site, Dublin

Investigational Site, Catanzaro

Investigational Site, Florence

Investigational Site, Naples

Investigational Site, Parma

Investigational Site, Rome

Investigational Site, Utrecht

Investigational Site, Oslo

Investigational Site, Ljubljana

Investigational Site, Barcelona

Investigational Site, Madrid

Investigational Site, Oviedo

Investigational Site, Lund

Investigational Site, Solna

Investigational Site, Canterbury

Investigational Site, Newcastle upon Tyne

Investigational Site, Oxford

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Syneos Health

OTHER

lead

Swedish Orphan Biovitrum

INDUSTRY